Imunon, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.5M
- Price
- $1.14
- % Change (Daily % change from the live per-ticker quote feed.)
- +1.79%
- Volume
- 107.6K
About
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Quick stats
Shares outstanding5.7M
Computed float—
Float / sharesUnknown
Cash runway (months)2.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000749647
Websitehttps://www.imunon.com
AI Summary
AI-generated1/21
minorbullishdebt offering
IMUNON Converts $1.2 Million of Debt-to-Equity
IMUNON exchanged $1.2 million of outstanding debt plus accrued interest for 120 shares of newly designated non-convertible Series B Preferred Stock, cutting outstanding debt by roughly 43%.
The preferred shares carry a $10,000 purchase price and $12,000 stated value per share, are not convertible into common stock, and are expected to be classified as permanent equity — with no new common shares or warrants issued.
The transaction provides no additional cash proceeds; management framed it as reducing future cash obligations while preserving flexibility for the Phase 3 OVATION 3 trial of lead asset IMNN-001.
Red flags
- transaction provides no additional cash proceeds — financing need remains
- forward-looking statements flag remaining A-1 Note obligations and Series B redemption obligations
- company discloses Nasdaq continued-listing compliance as a risk factor
- accounting treatment as permanent equity could be revised